Skip to main content
NCBI home page
Canadian Journal of Veterinary Research logoLink to Canadian Journal of Veterinary Research
. 2000 Apr;64(2):123–129.

Effect of clomipramine on monoamine metabolites in the cerebrospinal fluid of behaviorally normal dogs.

C J Hewson 1, U A Luescher 1, J M Parent 1, R O Ball 1
PMCID: PMC1189596  PMID: 10805252

Abstract

The tricyclic antidepressant, clomipramine, is an effective treatment for canine compulsive disorder (canine CD). This disorder is a clinical syndrome of abnormal conflict behaviors and its pathophysiology is unknown. However, because clomipramine is an effective treatment, information about the drug's neurochemical effect could enhance the understanding of canine CD. The following experiment used 6 behaviorally normal dogs to assess the effect of clomipramine (3 mg/kg, q24h, PO) on the central turnover of 3 monoamines (serotonin, dopamine, and norepinephrine) as measured by the concentrations of their respective metabolites in cerebrospinal fluid (CSF). In a randomized, placebo-controlled, AB-BA crossover experiment, cisternal CSF was taken after 1, 2, 4, and 6 wk on each treatment. No effect of clomipramine was detected. This contrasts with human studies that have suggested that clomipramine affects the concentrations of monoamine metabolites in lumbar CSF. However, those papers do not address methodological assumptions, such as (i) metabolites in CSF originate only from the brain, and (ii) concentrations of metabolites in cisternal/lumbar CSF reflect the concentrations in local areas of the brain. Notwithstanding the small sample size, our results suggest that more localized sampling techniques (e.g. microdialysis) are needed when examining the effect of drugs on central monoamine metabolites. Clomipramine's efficacy for canine CD indicates the need for neurobiological research and, to our knowledge, our study is the first of its kind in dogs. The resulting data are preliminary but they can inform optimal neurobiological studies of canine CD.

Full text

PDF
123

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adell A., Artigas F. Differential effects of clomipramine given locally or systemically on extracellular 5-hydroxytryptamine in raphe nuclei and frontal cortex. An in vivo brain microdialysis study. Naunyn Schmiedebergs Arch Pharmacol. 1991 Mar;343(3):237–244. doi: 10.1007/BF00251121. [DOI] [PubMed] [Google Scholar]
  2. Altemus M., Swedo S. E., Leonard H. L., Richter D., Rubinow D. R., Potter W. Z., Rapoport J. L. Changes in cerebrospinal fluid neurochemistry during treatment of obsessive-compulsive disorder with clomipramine. Arch Gen Psychiatry. 1994 Oct;51(10):794–803. doi: 10.1001/archpsyc.1994.03950100042004. [DOI] [PubMed] [Google Scholar]
  3. Asberg M., Ringberger V. A., Sjöqvist F., Thorén P., Träskman L., Tuck J. R. Monoamine metabolites in cerebrospinal fluid and serotonin uptake inhibition during treatment with chlorimipramine. Clin Pharmacol Ther. 1977 Feb;21(2):201–207. doi: 10.1002/cpt1977212201. [DOI] [PubMed] [Google Scholar]
  4. Benfield D. P., Harries C. M., Luscombe D. K. Some pharmacological aspects of desmethylclomipramine. Postgrad Med J. 1980;56 (Suppl 1):13–18. [PubMed] [Google Scholar]
  5. Bourgoin S., Ternaux J. P., Boireau A., Héry F., Hamon M. Effects of halothane and nitrous oxide anaesthesia on 5-HT turn-over in the rat brain. Naunyn Schmiedebergs Arch Pharmacol. 1975;288(2-3):109–121. doi: 10.1007/BF00500519. [DOI] [PubMed] [Google Scholar]
  6. Commissiong J. W. Monoamine metabolites: their relationship and lack of relationship to monoaminergic neuronal activity. Biochem Pharmacol. 1985 Apr 15;34(8):1127–1131. doi: 10.1016/0006-2952(85)90484-8. [DOI] [PubMed] [Google Scholar]
  7. DeMet E. M., Halaris A. E. Origin and distribution of 3-methoxy-4-hydroxyphenylglycol in body fluids. Biochem Pharmacol. 1979 Oct 15;28(20):3043–3050. doi: 10.1016/0006-2952(79)90611-7. [DOI] [PubMed] [Google Scholar]
  8. Eccleston D., Ashcroft G. W., Moir A. T., Parker-Rhodes A., Lutz W., O'Mahoney D. P. A comparison of 5-hydroxyindoles in various regions of dog brain and cerebrospinal fluid. J Neurochem. 1968 Sep;15(9):947–957. doi: 10.1111/j.1471-4159.1968.tb11637.x. [DOI] [PubMed] [Google Scholar]
  9. Faull K. F., Barchas J. D., Foutz A. S., Dement W. C., Holman R. B. Monoamine metabolite concentrations in the cerebrospinal fluid of normal and narcoleptic dogs. Brain Res. 1982 Jun 17;242(1):137–143. doi: 10.1016/0006-8993(82)90503-0. [DOI] [PubMed] [Google Scholar]
  10. Friedman E., Cooper T. B. Pharmacokinetics of chlorimipramine and its demethylated metabolite in blood and brain regions of rats treated acutely and chronically with chlorimipramine. J Pharmacol Exp Ther. 1983 May;225(2):387–390. [PubMed] [Google Scholar]
  11. Fujita K., Kobayashi A., Suzuki S., Nakazawa K. Changes of serotonin and catecholamines are related to pharmacokinetic alterations of clomipramine in rat brain. Eur J Pharmacol. 1991 Nov 12;204(3):227–233. doi: 10.1016/0014-2999(91)90846-i. [DOI] [PubMed] [Google Scholar]
  12. Godbillon J., Gauron S. Determination of clomipramine or imipramine and their mono-demethylated metabolites in human blood or plasma by high-performance liquid chromatography. J Chromatogr. 1981 Jan 16;204:303–311. doi: 10.1016/s0021-9673(00)81672-6. [DOI] [PubMed] [Google Scholar]
  13. Guldberg H. C., Ashcroft G. W., Crawford T. B. Concentrations of 5-hydroxyindolylacetic acid and homovanillic acid in the cerebrospinal fluid of the dog before and during treatment with probenecid. Life Sci. 1966 Sep;5(17):1571–1575. doi: 10.1016/0024-3205(66)91026-5. [DOI] [PubMed] [Google Scholar]
  14. Hall H., Ogren S. O. Effects of antidepressant drugs on different receptors in the brain. Eur J Pharmacol. 1981 Mar 26;70(3):393–407. doi: 10.1016/0014-2999(81)90172-2. [DOI] [PubMed] [Google Scholar]
  15. Hewson C. J., Conlon P. D., Luescher U. A., Ball R. O. The pharmacokinetics of clomipramine and desmethylclomipramine in dogs: parameter estimates following a single oral dose and 28 consecutive daily oral doses of clomipramine. J Vet Pharmacol Ther. 1998 Jun;21(3):214–222. doi: 10.1046/j.1365-2885.1998.00138.x. [DOI] [PubMed] [Google Scholar]
  16. Hewson C. J., Luescher U. A., Parent J. M., Conlon P. D., Ball R. O. Efficacy of clomipramine in the treatment of canine compulsive disorder. J Am Vet Med Assoc. 1998 Dec 15;213(12):1760–1766. [PubMed] [Google Scholar]
  17. Kapur S., Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry. 1996 Apr;153(4):466–476. doi: 10.1176/ajp.153.4.466. [DOI] [PubMed] [Google Scholar]
  18. Kobayashi K., Imazu Y., Kawabata M., Shohmori T. Effect of long-term storage on monoamine metabolite levels in human cerebrospinal fluid. Acta Med Okayama. 1987 Aug;41(4):179–181. doi: 10.18926/AMO/31735. [DOI] [PubMed] [Google Scholar]
  19. Kopin I. J. Catecholamine metabolism: basic aspects and clinical significance. Pharmacol Rev. 1985 Dec;37(4):333–364. [PubMed] [Google Scholar]
  20. Langlais P. J., Bird E. D., McEntee W. J. Stability of monoamine metabolites in human cerebrospinal fluid. Ann Neurol. 1982 Jul;12(1):48–51. doi: 10.1002/ana.410120109. [DOI] [PubMed] [Google Scholar]
  21. Linnoila M., Ninan P. T., Scheinin M., Waters R. N., Chang W. H., Bartko J., van Kammen D. P. Reliability of norepinephrine and major monoamine metabolite measurements in CSF of schizophrenic patients. Arch Gen Psychiatry. 1983 Dec;40(12):1290–1294. doi: 10.1001/archpsyc.1983.01790110032007. [DOI] [PubMed] [Google Scholar]
  22. Marder A. R. Psychotropic drugs and behavioral therapy. Vet Clin North Am Small Anim Pract. 1991 Mar;21(2):329–342. doi: 10.1016/s0195-5616(91)50036-x. [DOI] [PubMed] [Google Scholar]
  23. Mefford I. N., Foutz A., Noyce N., Jurik S. M., Handen C., Dement W. C., Barchas J. D. Distribution of norepinephrine, epinephrine, dopamine, serotonin, 3,4-dihydroxyphenylacetic acid, homovanillic acid and 5-hydroxyindole-3-acetic acid in dog brain. Brain Res. 1982 Mar 25;236(2):339–349. doi: 10.1016/0006-8993(82)90719-3. [DOI] [PubMed] [Google Scholar]
  24. Moir A. T., Ashcroft G. W., Crawford T. B., Eccleston D., Guldberg H. C. Cerebral metabolites in cerebrospinal fluid as a biochemical approach to the brain. Brain. 1970;93(2):357–368. doi: 10.1093/brain/93.2.357. [DOI] [PubMed] [Google Scholar]
  25. Rapoport J. L., Ryland D. H., Kriete M. Drug treatment of canine acral lick. An animal model of obsessive-compulsive disorder. Arch Gen Psychiatry. 1992 Jul;49(7):517–521. doi: 10.1001/archpsyc.1992.01820070011002. [DOI] [PubMed] [Google Scholar]
  26. Robins E., Guze S. B. Establishment of diagnostic validity in psychiatric illness: its application to schizophrenia. Am J Psychiatry. 1970 Jan;126(7):983–987. doi: 10.1176/ajp.126.7.983. [DOI] [PubMed] [Google Scholar]
  27. Scheinin M., Chang W. H., Kirk K. L., Linnoila M. Simultaneous determination of 3-methoxy-4-hydroxyphenylglycol, 5-hydroxyindoleacetic acid, and homovanillic acid in cerebrospinal fluid with high-performance liquid chromatography using electrochemical detection. Anal Biochem. 1983 May;131(1):246–253. doi: 10.1016/0003-2697(83)90162-8. [DOI] [PubMed] [Google Scholar]
  28. Sioufi A., Pommier F., Dubois J. P. Simultaneous determination of clomipramine and its N-desmethyl metabolite in human whole blood by capillary gas chromatography with mass-selective detection. J Chromatogr. 1988 Jun 24;428(1):71–80. doi: 10.1016/s0378-4347(00)83891-8. [DOI] [PubMed] [Google Scholar]
  29. Streiner D. L. An introduction to multivariate statistics. Can J Psychiatry. 1993 Feb;38(1):9–13. doi: 10.1177/070674379303800104. [DOI] [PubMed] [Google Scholar]
  30. Thomas P. C., Jones R. B. The effects of clomipramine and desmethylclomipramine on the in vitro uptake of radiolabelled 5-HT and noradrenaline into rat brain cortical slices. J Pharm Pharmacol. 1977 Sep;29(9):562–563. doi: 10.1111/j.2042-7158.1977.tb11398.x. [DOI] [PubMed] [Google Scholar]
  31. Thorén P., Asberg M., Bertilsson L., Mellström B., Sjöqvist F., Träskman L. Clomipramine treatment of obsessive-compulsive disorder. II. Biochemical aspects. Arch Gen Psychiatry. 1980 Nov;37(11):1289–1294. doi: 10.1001/archpsyc.1980.01780240087010. [DOI] [PubMed] [Google Scholar]
  32. Träskman L., Asberg M., Bertilsson L., Cronholm B., Mellström B., Neckers L. M., Sjöqvist F., Thorén P., Tybring G. Plasma levels of chlorimipramine and its demethyl metabolite during treatment of depression. Clin Pharmacol Ther. 1979 Nov;26(5):600–610. doi: 10.1002/cpt1979265600. [DOI] [PubMed] [Google Scholar]
  33. Vaughn D. M., Coleman E., Simpson S. T., Satjawatcharaphong C. Analysis of neurotransmitter metabolite concentrations in canine cerebrospinal fluid. Am J Vet Res. 1988 Aug;49(8):1302–1306. [PubMed] [Google Scholar]
  34. Westerink B. H., Lejeune B., Korf J., Van Praag H. M. On the significance of regional dopamine metabolism in the rat brain for the classification of centrally acting drugs. Eur J Pharmacol. 1977 Mar 21;42(2):179–190. doi: 10.1016/0014-2999(77)90358-2. [DOI] [PubMed] [Google Scholar]

Articles from Canadian Journal of Veterinary Research are provided here courtesy of Canadian Veterinary Medical Association

RESOURCES